Industry News

Agreement to Make GeneChip Technology Accessible to the Academic Community Announced

Published in Gene Therapy Weekly, May 3rd, 1999

Affymetrix, Inc., Santa Clara, California, and the U.S. National Cancer Institute (NCI), Bethesda, Maryland, announced that they have reached agreement on terms and conditions that will allow the biomedical research community broad access to Affymetrix' GeneChip probe array technology.

NCI and Affymetrix have agreed that the Affymetrix GeneChip technology will be available to academic and other not-for-profit scientific researchers in a manner that is consistent with the NCI's guidelines for the broad dissemination of research tools and Affymetrix' commercial goals. In particular, researchers will be able to publish scientific results via traditional and emerging...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1999-05-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry